Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma

Table 6 Results of phase II trials in esophageal cancer

Author	Regimen	Histology	Therapy line	Response rate (%)	TTP/PFS	OS
Lee [20]	XP (X:2,500 mg/m² D1-14 CDDP:60 mg/m²; D1)	SCC (n = 45)	1^st line (n = 45)	57.8%	4.7 mon	11.2 mon
Van Meerten [18]	XELOX (X:2,000 mg/m² D1-14 O:130 mg/m²; D1)	ADC (n = 45) SCC (n = 4) Undiff. (n = 2)	1^st line (n = 51)	39%	NR	8 mon
MB Polee [28]	Paclitaxel:180 mg/m²;D1 CDDP:60 mg/m²; D1	ADC (n = 31) SCC (n = 16) Undiff (n = 4)	1^st line (n = 51)	ADC (39%) SCC (44%)	NR	9 mon
Zhang [29]	Paclitaxel:175 mg/m² on D1 CDDP:75 mg/m² (D1)	SCC (n = 35)	1^st line (n = 35)	48.6%	7 mon	13 mon
S.Lorenzen [21]	DX (X:2,000 mg/m² D1-14 D:75 mg/m²; D1)	ADC (n = 7) SCC (n = 17)	1^st (n = 16) 2^nd (n = 8)	1^st (56%) 2^nd (25%) Overall = 46%	6.1 mon	1^st (15.8) 2^nd (6.2)
S.Lorenzen [26]	FP + Cetuximab vs FP	SCC (n = 62)	1^st line (n = 62)	FP+ Cetuximab (19%) FP (13%)	5.9 mon 3.6 mon	9.5 mon 5.5 mon
Current Study	Xeloda 1,800 mg/m² D1-14 Paclitaxel:80 mg/m² on D1, D8	SCC (n = 32)	1^st (n = 12) 2^nd (n = 20)	1^st (75%) 2^nd (45%) Overall = 53.6%	5.23 mon 4.54 mon	14.3 mon 8.4 mon

Abbreviations: XP, capecitabine/cisplatin; XELOX, capecitabine/oxaliplatin; DX, docetaxel/capecitabine; FP, 5-fluorouracil/cisplatin; SCC, squamous cell carcinoma; ADC, adenocarcinoma; Undiff, undifferentiated carcinoma; TTP, time to progression; PFS, progression-free survival; OS, overall survival; NR, not reported.

ISSN: 1471-2407